192 related articles for article (PubMed ID: 37675835)
1. Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.
Douguet L; Fert I; Lopez J; Vesin B; Le Chevalier F; Moncoq F; Authié P; Nguyen TM; Noirat A; Névo F; Blanc C; Bourgine M; Hardy D; Anna F; Majlessi L; Charneau P
EMBO Mol Med; 2023 Oct; 15(10):e17723. PubMed ID: 37675835
[TBL] [Abstract][Full Text] [Related]
2. T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.
Fert I; Douguet L; Vesin B; Moncoq F; Noirat A; Authié P; Ciret S; Le Chevalier F; Blanc C; Vitrenko Y; Charneau P; Majlessi L; Anna F
NPJ Vaccines; 2024 Jun; 9(1):102. PubMed ID: 38858404
[TBL] [Abstract][Full Text] [Related]
3. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
4. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA
Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
[TBL] [Abstract][Full Text] [Related]
7. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16
Salomon N; Selmi A; Grunwitz C; Kong A; Stanganello E; Neumaier J; Petschenka J; Diken M; Kreiter S; Türeci Ö; Sahin U; Vascotto F
Cancer Immunol Immunother; 2022 Aug; 71(8):1975-1988. PubMed ID: 34971406
[TBL] [Abstract][Full Text] [Related]
8. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory.
Grunwitz C; Salomon N; Vascotto F; Selmi A; Bukur T; Diken M; Kreiter S; Türeci Ö; Sahin U
Oncoimmunology; 2019; 8(9):e1629259. PubMed ID: 31428528
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
10. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
[TBL] [Abstract][Full Text] [Related]
12. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
13. Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16
Lin YH; Yang MC; Tseng SH; Jiang R; Yang A; Farmer E; Peng S; Henkle T; Chang YN; Hung CF; Wu TC
Cancer Immunol Res; 2018 Mar; 6(3):305-319. PubMed ID: 29362220
[TBL] [Abstract][Full Text] [Related]
14. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
Schmidt S; Bonilla WV; Reiter A; Stemeseder F; Kleissner T; Oeler D; Berka U; El-Gazzar A; Kiefmann B; Schulha SC; Raguz J; Habbeddine M; Scheinost M; Qing X; Lauterbach H; Matushansky I; Pinschewer DD; Orlinger KK
Oncoimmunology; 2020 Sep; 9(1):1809960. PubMed ID: 33457095
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
16. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
17. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
18. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors.
Paolini F; Amici C; Carosi M; Bonomo C; Di Bonito P; Venuti A; Accardi L
J Exp Clin Cancer Res; 2021 Jan; 40(1):37. PubMed ID: 33485370
[TBL] [Abstract][Full Text] [Related]
19. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice.
Boilesen DR; Neckermann P; Willert T; Müller MD; Schrödel S; Pertl C; Thirion C; Asbach B; Wagner R; Holst PJ
Cancer Immunol Res; 2023 Feb; 11(2):261-275. PubMed ID: 36534088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
